Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and obinutuzumab versus obinutuzumab and chlorambucil in previously untreated chronic lymphocytic leukemia
2014-005582-73Phase 3Unknown
- Sponsor
- Acerta Pharma
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib, obinutuzumab and chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
acalabrutinibobinutuzumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2014-005582-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005582-73.